The cGAS-STING pathway is a master regulator of OCT4 expression in persistent sarcoma cells and enhances cellular immunotherapy with NK and CIK lymphocytes
Cancer Immunology, Immunotherapy · 2025
DOI: 10.1007/s00262-025-04141-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Giorgia Giordano und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy. Hauptthemen laut MEDLINE: cGAS-STING Signaling Pathway, Immunotherapy, Killer Cells, Natural, Cytokine-Induced Killer Cells. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Associazione Italiana per la Ricerca sul Cancro, PON 2014-2020 DM 1062/2021, PharmaMar.
Abstract (Originalsprache)
Advanced sarcomas have a poor prognosis and limited therapeutic options. Disease recurrence is caused by persistent cells that survive drug treatments. The alkylating agent trabectedin, when combined with the poly (ADP-ribose) polymerase 1 (PARP1) inhibitor olaparib, exhibits variable antitumor effects in advanced sarcomas. In this study, we demonstrate that the expression of the transcription factor OCT4 is upregulated in persistent cells that survive treatment with trabectedin and olaparib, through the cGAS-STING-IRF3-IFNβ pathway. This route also leads to the upregulation of natural killer (NK) and cytokine-induced killer (CIK) lymphocyte activating ligands. These molecular events enhance the antitumor efficacy of immunotherapy with NK and CIK cells, targeting both the bulk population and residual drug-tolerant cells. In conclusion, the activation of the cGAS-STING pathway has a double-edged effect, enriching the OCT4 + persistent cell population while increasing the expression of NK/CIK ligands. The addition of olaparib to trabectedin potentiates the cGAS-STING pathway activation and the upregulation of NKG2DLs, while simultaneously counteracting the OCT4 overexpression. Therefore, sequential treatment with trabectedin and olaparib followed by NK/CIK immunotherapy represents a promising strategy against advanced sarcomas and warrants further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.
- Department of Clinical and Biological Sciences, University of Torino, Turin, Italy.
- Department of Oncology, University of Torino, Turin, Italy. alessandra.merlini@unito.it.
- Medical Oncology, San Luigi Gonzaga University Hospital, Orbassano, Turin, Italy. alessandra.merlini@unito.it.
- Italian Institute for Genomic Medicine (IIGM), Turin, Italy.
- Department of Oncology, University of Torino, Turin, Italy.
Förderung
- Associazione Italiana per la Ricerca sul Cancro
- PON 2014-2020 DM 1062/2021
- PharmaMar
- Fondazione Piemontese per la ricerca sul cancro
- Fondazione per la ricerca sui tumori dell'apparato muscoloscheletrico e rari ONLUS
- Ministero della Salute
- Alleanza contro il cancro
Zitieren
APA
Giordano, G., Merlini, A., Capozzi, F., Ferrero, G., Tucciarello, C., Majidi, S., Comparato, S., Mesiano, G., Liuzzi, E., Galvagno, F., Massa, A., Brusco, S., Leuci, V., Riganti, C., Cutrupi, S., De Bortoli, M., D'Ambrosio, L., Sangiolo, D., Grignani, G., & Pignochino, Y. (2025). The cGAS-STING pathway is a master regulator of OCT4 expression in persistent sarcoma cells and enhances cellular immunotherapy with NK and CIK lymphocytes. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04141-w
Vancouver
Giordano G, Merlini A, Capozzi F, Ferrero G, Tucciarello C, Majidi S, et al. The cGAS-STING pathway is a master regulator of OCT4 expression in persistent sarcoma cells and enhances cellular immunotherapy with NK and CIK lymphocytes. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04141-w
BibTeX
@article{Giordano2025,
author = {Giordano, Giorgia and Merlini, Alessandra and Capozzi, Federica and Ferrero, Giulio and Tucciarello, Cristina and Majidi, Shahab and Comparato, Simona and Mesiano, Giulia and Liuzzi, Elisabetta and Galvagno, Federica and Massa, Annamaria and Brusco, Silvia and Leuci, Valeria and Riganti, Chiara and Cutrupi, Santina and De Bortoli, Michele and D'Ambrosio, Lorenzo and Sangiolo, Dario and Grignani, Giovanni and Pignochino, Ymera},
title = {The cGAS-STING pathway is a master regulator of OCT4 expression in persistent sarcoma cells and enhances cellular immunotherapy with NK and CIK lymphocytes},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
doi = {10.1007/s00262-025-04141-w}
}
EUVIMED